Accelerated approval pathways create an additional layer of complexity in the chaotic oncology marketplace, leaving manufacturers of all sizes seeking a new commercialization model for launch success.
With 30% of drug approvals by the FDA occurring in the oncology and hematology space, there is considerable focus by biotechnology manufacturers to fulfill the unmet need of cancer therapies that can extend throughout the span of the patient’s life. This unmet need, and the pace of the biotechnology industry, can lead these high-science brands to participate in accelerated approval pathways.
Accelerated approval pathways create an additional layer of complexity in the chaotic oncology marketplace, leaving manufacturers of all sizes seeking a new commercialization model for launch success.
This article will explore:
Offered Free by: EVERSANA
See All Resources from: EVERSANA
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.